{"id":134391,"date":"2026-09-22T08:31:10","date_gmt":"2026-09-22T08:31:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/134391\/"},"modified":"2026-09-22T08:31:10","modified_gmt":"2026-09-22T08:31:10","slug":"novartis-licenses-boomray-radioligand-asset-for-900m","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/134391\/","title":{"rendered":"Novartis licenses BoomRay radioligand asset for $900M"},"content":{"rendered":"<p class=\"PDq2pG_selectionAnchorContainer\" dir=\"auto\" data-start=\"638\" data-end=\"923\">By the numbers: BoomRay will receive an undisclosed upfront payment and is eligible for development, regulatory and sales milestones, bringing the potential total to $900 million. The company could also receive royalties on future global sales.<\/p>\n<p>Few other details were disclosed, including the asset\u2019s target, isotope or indication. BoomRay described the program only as a preclinical radioligand therapy.<\/p>\n<p dir=\"auto\" data-start=\"1086\" data-end=\"1497\">The big picture: Radioligand therapies have become a major part of Novartis\u2019 oncology strategy. The Swiss group entered the field through its $3.9 billion acquisition of Advanced Accelerator Applications in 2018, bringing in Lutathera, before paying $2.1 billion for Endocyte later that year and gaining the program that eventually became prostate cancer drug Pluvicto.<\/p>\n<p>Novartis has continued investing in the technology. In 2024, it agreed to buy Mariana Oncology for $1 billion upfront plus up to $750 million in milestones, adding a preclinical radioligand pipeline and research infrastructure. It is also developing next-generation approaches, including actinium-225-based therapies.<\/p>\n<p dir=\"auto\" data-start=\"1856\" data-end=\"2246\">Why it matters: The BoomRay deal comes just one day after another major radiopharma transaction: Australia\u2019s Telix Pharmaceuticals agreed to <a href=\"https:\/\/european-biotechnology.com\/latest-news\/telix-to-acquire-itm-for-1-65b-in-radiopharma-push\/\" rel=\"nofollow noopener\" target=\"_blank\">acquire Munich-based ITM<\/a> for an initial $1.65 billion (\u20ac1.44 billion) paid mostly in Telix\u2019s shares. That deal combines Telix\u2019s commercial radiopharma business with ITM\u2019s isotope manufacturing network and late-stage therapeutic pipeline.<\/p>\n","protected":false},"excerpt":{"rendered":"By the numbers: BoomRay will receive an undisclosed upfront payment and is eligible for development, regulatory and sales&hellip;\n","protected":false},"author":2,"featured_media":134392,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[14272,206],"class_list":["post-134391","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-licensing","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117313764303605497","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/134391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=134391"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/134391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/134392"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=134391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=134391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=134391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}